SEC Info - X4 Pharmaceuticals, Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

X4 Pharmaceuticals, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Thursday, 3/21/24, at 5:08pm ET · For: 12/31/23 · Accession #: 1628280-24-12578 · File #: 1-38295

Previous ‘10-K’: ‘10-K’ on 3/21/23 for 12/31/22 · Latest ‘10-K’: This Filing · 28 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  X4 Pharmaceuticals, Inc.          10-K       12/31/23   93:9.5M                                   Workiva Inc Wde… FA01/FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.97M 
 2: EX-10.37    Material Contract                                   HTML     33K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
 7: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     49K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
13: R1          Cover                                               HTML     95K 
14: R2          Audit Information                                   HTML     32K 
15: R3          Consolidated Balance Sheets                         HTML    124K 
16: R4          Consolidated Balance Sheets (Parenthetical)         HTML     37K 
17: R5          Consolidated Statements of Operations and           HTML    104K 
                Comprehensive Loss                                               
18: R6          Consolidated Statements of Convertible Preferred    HTML    117K 
                Stock, Redeemable Common Stock and Stockholders'                 
                Equity (Deficit)                                                 
19: R7          Consolidated Statements of Cash Flows               HTML    120K 
20: R8          Nature of the Business and Basis of Presentation    HTML     37K 
21: R9          Summary of Significant Accounting Policies          HTML     88K 
22: R10         License, Collaboration, and Funding Agreements      HTML     47K 
23: R11         Fair Value of Financial Assets and Liabilities      HTML    129K 
24: R12         Property and Equipment, Net                         HTML     40K 
25: R13         Accrued Expenses                                    HTML     37K 
26: R14         Long-Term Debt                                      HTML     57K 
27: R15         Leases                                              HTML     56K 
28: R16         Commitment and Contingencies                        HTML     33K 
29: R17         Preferred and Common Stock Warrants                 HTML     81K 
30: R18         Common Stock, Redeemable Common Stock and           HTML     48K 
                Convertible Preferred Stock (converted to Common                 
                Stock)                                                           
31: R19         Stock-Based Compensation                            HTML     87K 
32: R20         Income Taxes                                        HTML     89K 
33: R21         Net Loss per Share                                  HTML     52K 
34: R22         Loss on Transfer of Nonfinancial Assets             HTML     31K 
35: R23         Summary of Significant Accounting Policies          HTML    117K 
                (Policies)                                                       
36: R24         Summary of Significant Accounting Policies          HTML     55K 
                (Tables)                                                         
37: R25         Fair Value of Financial Assets and Liabilities      HTML    137K 
                (Tables)                                                         
38: R26         Property and Equipment, Net (Tables)                HTML     39K 
39: R27         Accrued Expenses (Tables)                           HTML     37K 
40: R28         Long-Term Debt (Tables)                             HTML     52K 
41: R29         Leases (Tables)                                     HTML     55K 
42: R30         Preferred and Common Stock Warrants (Tables)        HTML     78K 
43: R31         Stock-Based Compensation (Tables)                   HTML     75K 
44: R32         Income Taxes (Tables)                               HTML     88K 
45: R33         Net Loss per Share (Tables)                         HTML     52K 
46: R34         Nature of the Business and Basis of Presentation    HTML     56K 
                (Details)                                                        
47: R35         Summary of Significant Accounting Policies -        HTML     46K 
                Schedule of Restricted Cash (Details)                            
48: R36         Summary of Significant Accounting Policies -        HTML     39K 
                Schedule of Cash, Cash Equivalents and Restricted                
                Cash (Details)                                                   
49: R37         Summary of Significant Accounting Policies -        HTML     40K 
                Schedule of Property, Plant and Equipment                        
                (Details)                                                        
50: R38         Summary of Significant Policies - Additional        HTML     38K 
                Information (Details)                                            
51: R39         License, Collaboration, and Funding Agreements -    HTML     54K 
                Genzyme Agreement (Details)                                      
52: R40         License, Collaboration, and Funding Agreements -    HTML     39K 
                Georgetown Agreement (Details)                                   
53: R41         License, Collaboration, and Funding Agreements -    HTML     47K 
                Beth Israel Deaconess Medical Center Agreements                  
                (Details)                                                        
54: R42         License, Collaboration, and Funding Agreements -    HTML     41K 
                Research and Development Incentive Program                       
                (Details)                                                        
55: R43         License, Collaboration, and Funding Agreements      HTML     30K 
                (Details)                                                        
56: R44         Fair Value of Financial Assets and Liabilities -    HTML     74K 
                Measured on a Recurring Basis (Details)                          
57: R45         Fair Value of Financial Assets and Liabilities -    HTML     45K 
                Debt Securities Available-for-Sale (Details)                     
58: R46         Fair Value of Financial Assets and Liabilities -    HTML     53K 
                Narrative (Details)                                              
59: R47         Fair Value of Financial Assets and Liabilities      HTML     55K 
                -Aggregate Fair Value of Warrant and Derivative                  
                Liabilities (Details)                                            
60: R48         Fair Value of Financial Assets and Liabilities -    HTML     50K 
                Assumptions (Details)                                            
61: R49         Fair Value of Financial Assets and Liabilities -    HTML     42K 
                Goodwill Rollforward (Details)                                   
62: R50         Property and Equipment, Net (Details)               HTML     49K 
63: R51         Accrued Expenses (Details)                          HTML     39K 
64: R52         Long-Term Debt - Schedule of Long-Term Debt         HTML     41K 
                (Details)                                                        
65: R53         Long-Term Debt - Narrative (Details)                HTML     63K 
66: R54         Long-Term Debt - Hercules Loan Agreements           HTML     35K 
                (Details)                                                        
67: R55         Long-Term Debt - Future Principal Payments          HTML     37K 
                (Details)                                                        
68: R56         Leases (Details)                                    HTML     79K 
69: R57         Leases - Schedule of Components of Lease Expense    HTML     47K 
                (Details)                                                        
70: R58         Leases - Schedule of Maturities of Lease            HTML     44K 
                Liabilities (Detail)                                             
71: R59         Preferred and Common Stock Warrants - Additional    HTML     84K 
                Information (Details)                                            
72: R60         Preferred and Common Stock Warrants - Schedule of   HTML     50K 
                Outstanding Warrants (Detail)                                    
73: R61         Preferred and Common Stock Warrants - Summary of    HTML    103K 
                Outstanding Warrants to Purchase Shares of Common                
                Stock (Details)                                                  
74: R62         Common Stock, Redeemable Common Stock and           HTML    192K 
                Convertible Preferred Stock (converted to Common                 
                Stock) - Additional Information (Details)                        
75: R63         Stock-Based Compensation - Additional Information   HTML     94K 
                (Details)                                                        
76: R64         Stock-Based Compensation - Summary of Stock Option  HTML     79K 
                Activity (Detail)                                                
77: R65         Stock-Based Compensation - Restricted Stock Units   HTML     38K 
                (Details)                                                        
78: R66         Stock-Based Compensation - Summary of Stock-Based   HTML     42K 
                Compensation Expense Classification (Details)                    
79: R67         Stock-Based Compensation - Stock Option Valuation   HTML     52K 
                (Details)                                                        
80: R68         Income Taxes - Schedule of Income Loss Before       HTML     37K 
                Income Taxes (Details)                                           
81: R69         Income Taxes - Reconciliation of Effective Income   HTML     44K 
                Tax Rate (Details)                                               
82: R70         Income Taxes - Deferred Income Tax Asset (Details)  HTML     50K 
83: R71         Income Taxes - Narrative (Details)                  HTML     48K 
84: R72         Income Taxes - Deferred Tax Valuation Allowance     HTML     33K 
                (Details)                                                        
85: R73         Income Taxes (Details)                              HTML     31K 
86: R74         Net Loss per Share - Summary of Basic and Diluted   HTML     65K 
                Net loss per Share Attributable to Common                        
                Stockholders (Details)                                           
87: R75         Net Loss per Share - Additional Information         HTML     39K 
                (Details)                                                        
88: R76         Net Loss per Share - Schedule of Anti-dilutive      HTML     38K 
                Securities Excluded from Computation of Diluted                  
                Net Loss per Share Attributable to Common                        
                Stockholders (Details)                                           
90: XML         IDEA XML File -- Filing Summary                      XML    170K 
93: XML         XBRL Instance -- xfor-20231231_htm                   XML   1.90M 
89: EXCEL       IDEA Workbook of Financial Report Info              XLSX    199K 
 9: EX-101.CAL  XBRL Calculations -- xfor-20231231_cal               XML    190K 
10: EX-101.DEF  XBRL Definitions -- xfor-20231231_def                XML    760K 
11: EX-101.LAB  XBRL Labels -- xfor-20231231_lab                     XML   1.70M 
12: EX-101.PRE  XBRL Presentations -- xfor-20231231_pre              XML   1.22M 
 8: EX-101.SCH  XBRL Schema -- xfor-20231231                         XSD    212K 
91: JSON        XBRL Instance as JSON Data -- MetaLinks              523±   804K 
92: ZIP         XBRL Zipped Folder -- 0001628280-24-012578-xbrl      Zip    586K

‘EX-101.CAL’ — XBRL Calculations — xfor-20231231_cal

This Exhibit is an XBRL File.

<?xml version="1.0" encoding="windows-1252"?>

<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="xfor-20231231.xsd#ConsolidatedBalanceSheets"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a95387ad-efa4-4a73-8a2b-26c961573ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:to="loc_us-gaap_AssetsCurrent_a95387ad-efa4-4a73-8a2b-26c961573ca9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_176b90ba-7ebb-4454-82f8-d854e101cb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_176b90ba-7ebb-4454-82f8-d854e101cb0a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2ec69ba3-94c4-4f9e-8bf7-603569c54399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2ec69ba3-94c4-4f9e-8bf7-603569c54399" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ea22d424-041f-463b-bc2b-bcbaa0bb650b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:to="loc_us-gaap_Goodwill_ea22d424-041f-463b-bc2b-bcbaa0bb650b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e9dfd12f-adcc-460c-9292-d2e21d6d2517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_062765a4-e76b-4d70-ba5b-50a4e160ceee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e9dfd12f-adcc-460c-9292-d2e21d6d2517" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9f3590cc-68a8-4f1f-b878-038fa4f141af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a60b7704-ed23-4715-a6cc-59a0bf6eafa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9f3590cc-68a8-4f1f-b878-038fa4f141af" xlink:to="loc_us-gaap_CommonStockValue_a60b7704-ed23-4715-a6cc-59a0bf6eafa9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2973e68-8b65-42bf-bdae-cb3cb1922191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9f3590cc-68a8-4f1f-b878-038fa4f141af" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2973e68-8b65-42bf-bdae-cb3cb1922191" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2590c5d6-4359-4acb-b08b-d1eefb0ee3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9f3590cc-68a8-4f1f-b878-038fa4f141af" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2590c5d6-4359-4acb-b08b-d1eefb0ee3bb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7f99eb66-25bf-48c8-a3c9-a1a7745ce589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9f3590cc-68a8-4f1f-b878-038fa4f141af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7f99eb66-25bf-48c8-a3c9-a1a7745ce589" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_407190a8-01de-4f1e-b561-310866c3b03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b11c530-c11c-4d30-983e-8c1e57ac4e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_407190a8-01de-4f1e-b561-310866c3b03c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b11c530-c11c-4d30-983e-8c1e57ac4e80" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3fa9b7b-c0e7-4d54-b12e-925dd6a670a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_407190a8-01de-4f1e-b561-310866c3b03c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e3fa9b7b-c0e7-4d54-b12e-925dd6a670a6" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5cb3730d-61f7-44e6-ad73-fd0abef76620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_407190a8-01de-4f1e-b561-310866c3b03c" xlink:to="loc_us-gaap_AccountsPayableCurrent_5cb3730d-61f7-44e6-ad73-fd0abef76620" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1af70b68-1b2a-40e3-b4ad-07e9659ad84b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_407190a8-01de-4f1e-b561-310866c3b03c" xlink:to="loc_us-gaap_LongTermDebtCurrent_1af70b68-1b2a-40e3-b4ad-07e9659ad84b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e10ccc4-abe5-45fc-bf14-9b42875f9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_162e9edb-2607-4717-9e86-438130443f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e10ccc4-abe5-45fc-bf14-9b42875f9a99" xlink:to="loc_us-gaap_Liabilities_162e9edb-2607-4717-9e86-438130443f2d" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a159302b-931f-4588-9f15-23dda838ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e10ccc4-abe5-45fc-bf14-9b42875f9a99" xlink:to="loc_us-gaap_StockholdersEquity_a159302b-931f-4588-9f15-23dda838ad63" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5f06fecf-ddf7-42e2-89ca-d47e0a2c203b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e10ccc4-abe5-45fc-bf14-9b42875f9a99" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5f06fecf-ddf7-42e2-89ca-d47e0a2c203b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_d17c8877-d2ca-4eca-9cff-ffd3f296dcec" xlink:href="xfor-20231231.xsd#xfor_LongTermDebtNonCurrentIncludingAccrection"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_d17c8877-d2ca-4eca-9cff-ffd3f296dcec" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_167632b1-f4a2-4ba1-9307-f9813ae4c63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_167632b1-f4a2-4ba1-9307-f9813ae4c63f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_55b1e145-1445-4157-a223-39a61f946d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:to="loc_us-gaap_LiabilitiesCurrent_55b1e145-1445-4157-a223-39a61f946d67" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc6f53af-db94-48ef-895a-05ca3a14f4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc6f53af-db94-48ef-895a-05ca3a14f4fd" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_539723e7-f110-4b6e-9456-b2e24817e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9852b007-9d07-4344-8dfb-0a0e30f1d695" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_539723e7-f110-4b6e-9456-b2e24817e30b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f1e2578-51c4-4775-8dba-a17594dad0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_21fcf553-b269-4d1b-8d1e-0f4d377a779a" xlink:href="xfor-20231231.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f1e2578-51c4-4775-8dba-a17594dad0f0" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_21fcf553-b269-4d1b-8d1e-0f4d377a779a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33fb3dd1-d2d8-4ca2-9f5f-4448c86c6082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f1e2578-51c4-4775-8dba-a17594dad0f0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33fb3dd1-d2d8-4ca2-9f5f-4448c86c6082" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74eeb386-f9e4-4655-9f2d-e21789a71dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f1e2578-51c4-4775-8dba-a17594dad0f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74eeb386-f9e4-4655-9f2d-e21789a71dd5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_5f7623a4-6959-4e9d-945b-64b6ab919018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f1e2578-51c4-4775-8dba-a17594dad0f0" xlink:to="loc_us-gaap_MarketableSecurities_5f7623a4-6959-4e9d-945b-64b6ab919018" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="xfor-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_01950c52-0de2-4cc3-8c59-7714a57d0c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ea4a97fd-daef-4a62-bfb4-eb22fc18ee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_01950c52-0de2-4cc3-8c59-7714a57d0c8c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ea4a97fd-daef-4a62-bfb4-eb22fc18ee3a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_99efb0f9-811d-4b37-ad39-bc6a902ea5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_01950c52-0de2-4cc3-8c59-7714a57d0c8c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_99efb0f9-811d-4b37-ad39-bc6a902ea5eb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_65c0c7ec-054c-4a0c-8f2a-57fd76547dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_01950c52-0de2-4cc3-8c59-7714a57d0c8c" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_65c0c7ec-054c-4a0c-8f2a-57fd76547dd6" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6df8eebd-8a03-49b2-8766-4797f043d11c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_01950c52-0de2-4cc3-8c59-7714a57d0c8c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6df8eebd-8a03-49b2-8766-4797f043d11c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0bbeabac-ff2d-459b-97d1-d9857fc91efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fe731d64-8a0a-43b1-82cd-0f359369a5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0bbeabac-ff2d-459b-97d1-d9857fc91efe" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fe731d64-8a0a-43b1-82cd-0f359369a5d8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_97b0d79e-b4f7-4fca-8f44-9a8cacc563d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0bbeabac-ff2d-459b-97d1-d9857fc91efe" xlink:to="loc_us-gaap_InterestExpense_97b0d79e-b4f7-4fca-8f44-9a8cacc563d7" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_790296ff-08f5-46df-a1f9-4d2c67c014b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0bbeabac-ff2d-459b-97d1-d9857fc91efe" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_790296ff-08f5-46df-a1f9-4d2c67c014b2" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_551e3607-d5b4-449d-9223-7334c814819d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0bbeabac-ff2d-459b-97d1-d9857fc91efe" xlink:to="loc_us-gaap_InvestmentIncomeInterest_551e3607-d5b4-449d-9223-7334c814819d" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bfdee1f7-46a5-4858-b229-67a674b76aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_26a4a324-b621-4986-ba0d-981b6a97c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bfdee1f7-46a5-4858-b229-67a674b76aa7" xlink:to="loc_us-gaap_NetIncomeLoss_26a4a324-b621-4986-ba0d-981b6a97c5d6" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_2aa5cdc6-156e-4f27-b568-02f4b0ac2fe5" xlink:href="xfor-20231231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bfdee1f7-46a5-4858-b229-67a674b76aa7" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_2aa5cdc6-156e-4f27-b568-02f4b0ac2fe5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32a97d70-4490-49ad-9edb-316f91e19d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39904c6f-9b79-4d10-949a-0427ebbb7de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32a97d70-4490-49ad-9edb-316f91e19d51" xlink:to="loc_us-gaap_OperatingIncomeLoss_39904c6f-9b79-4d10-949a-0427ebbb7de4" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5e36976a-1a6c-4d6b-be51-827752d3482d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32a97d70-4490-49ad-9edb-316f91e19d51" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5e36976a-1a6c-4d6b-be51-827752d3482d" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8b5e34d9-697a-444a-9f41-ed0b293fc78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3db7da03-1c68-4f33-9128-e7e0ad296cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8b5e34d9-697a-444a-9f41-ed0b293fc78b" xlink:to="loc_us-gaap_OperatingExpenses_3db7da03-1c68-4f33-9128-e7e0ad296cef" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c665b21-f6d4-420e-9e5d-8a624626294e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bebba321-513e-4c25-a6eb-ddd2b2bbd111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c665b21-f6d4-420e-9e5d-8a624626294e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bebba321-513e-4c25-a6eb-ddd2b2bbd111" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0158e566-7a8c-4c25-8b6d-b9c6d2d81614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c665b21-f6d4-420e-9e5d-8a624626294e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0158e566-7a8c-4c25-8b6d-b9c6d2d81614" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="xfor-20231231.xsd#ConsolidatedStatementsofCashFlows"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_56563e95-b117-4302-8888-712b0294d828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_56563e95-b117-4302-8888-712b0294d828" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_49cbed9f-9df8-4f7b-8731-c1a7439d5795" xlink:href="xfor-20231231.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_49cbed9f-9df8-4f7b-8731-c1a7439d5795" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_c6bd8f30-69d0-4223-a992-51177492975e" xlink:href="xfor-20231231.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_c6bd8f30-69d0-4223-a992-51177492975e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_2d2f6592-cfd1-4d58-839b-7383f3fa1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_2d2f6592-cfd1-4d58-839b-7383f3fa1b6c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df40641a-7390-45b7-9a7b-fddff7e8822e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>

<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df40641a-7390-45b7-9a7b-fddff7e8822e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0fb8e53b-8d67-407b-9928-652f262360fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>

<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0fb8e53b-8d67-407b-9928-652f262360fb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_3c7ad72b-a4ea-4760-9120-7d868ac5f8bb" xlink:href="xfor-20231231.xsd#xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement"/>

<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef468144-b303-48f0-a5a0-d5419db963a5" xlink:to="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_3c7ad72b-a4ea-4760-9120-7d868ac5f8bb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42408024-655d-4643-b429-f0b177464dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba4c01d6-678d-46c6-852f-1f3c31520cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42408024-655d-4643-b429-f0b177464dde" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba4c01d6-678d-46c6-852f-1f3c31520cc9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68d81482-0172-40a3-a089-fcac981b8eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42408024-655d-4643-b429-f0b177464dde" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68d81482-0172-40a3-a089-fcac981b8eaa" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c87db4e0-fe03-48a3-ab3e-8779b957a24e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42408024-655d-4643-b429-f0b177464dde" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c87db4e0-fe03-48a3-ab3e-8779b957a24e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19e78c36-21a7-4365-85a8-0c9115e238cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42408024-655d-4643-b429-f0b177464dde" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19e78c36-21a7-4365-85a8-0c9115e238cb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09f0bad0-f7d4-4062-85c6-af6960bde603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09f0bad0-f7d4-4062-85c6-af6960bde603" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_85f41d07-cf97-4512-9c0b-2bf79aaae45e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_ProfitLoss_85f41d07-cf97-4512-9c0b-2bf79aaae45e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_3282a19c-ac93-4f6d-ab90-0241dc7635d1" xlink:href="xfor-20231231.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_3282a19c-ac93-4f6d-ab90-0241dc7635d1" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_52b3c21e-ac77-4f60-b390-ec2a546f65a4" xlink:href="xfor-20231231.xsd#xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_52b3c21e-ac77-4f60-b390-ec2a546f65a4" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_080a9668-888f-4acc-b94f-bad68ddd2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_080a9668-888f-4acc-b94f-bad68ddd2a53" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_ec8b68f5-755b-46cf-a803-ff4e85bd1045" xlink:href="xfor-20231231.xsd#xfor_NonCashLeaseExpense"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_xfor_NonCashLeaseExpense_ec8b68f5-755b-46cf-a803-ff4e85bd1045" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_9eed61c8-7a39-4eb1-945d-3580fccdf7aa" xlink:href="xfor-20231231.xsd#xfor_NonCashInterestExpense"/>

<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_xfor_NonCashInterestExpense_9eed61c8-7a39-4eb1-945d-3580fccdf7aa" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_237a8414-c5b8-45ca-ac89-3ff70ac7575e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>

<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_237a8414-c5b8-45ca-ac89-3ff70ac7575e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_79556b2b-34ed-4679-a7fb-d4e2811e53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>

<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_ShareBasedCompensation_79556b2b-34ed-4679-a7fb-d4e2811e53a0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a6a26182-b212-43e2-897a-ad51adac43b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>

<link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a6a26182-b212-43e2-897a-ad51adac43b4" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_121d7ea0-aad7-497e-bc1a-fd45d28b050b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>

<link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_121d7ea0-aad7-497e-bc1a-fd45d28b050b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_3091991f-5b4d-4887-ae46-64dc43c00bb5" xlink:href="xfor-20231231.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>

<link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_3091991f-5b4d-4887-ae46-64dc43c00bb5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b5d9d9e1-241b-4edf-a92f-e62e6af2dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>

<link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_610497ea-0d21-4e7c-90ec-7ca37b93dd3a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b5d9d9e1-241b-4edf-a92f-e62e6af2dcf7" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_681c7649-87a5-4dd6-8dd6-4d94569af823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5f8bcea3-b830-4d69-9576-919fa47a18c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_681c7649-87a5-4dd6-8dd6-4d94569af823" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5f8bcea3-b830-4d69-9576-919fa47a18c1" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9422642d-80a9-4727-aa25-c560adefa265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_681c7649-87a5-4dd6-8dd6-4d94569af823" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9422642d-80a9-4727-aa25-c560adefa265" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_a07c0307-a65c-4891-8166-524c1d4a9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_681c7649-87a5-4dd6-8dd6-4d94569af823" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_a07c0307-a65c-4891-8166-524c1d4a9a99" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1283918a-10f5-41d1-8d14-f43388b411f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5909b821-6fcf-487a-9652-df769e32d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1283918a-10f5-41d1-8d14-f43388b411f7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5909b821-6fcf-487a-9652-df769e32d5c0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f187831-528d-49e3-a3e8-e9e80b7ce7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1283918a-10f5-41d1-8d14-f43388b411f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f187831-528d-49e3-a3e8-e9e80b7ce7e8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ba0d56e9-43d3-429b-bad2-cc4d32a8d806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1283918a-10f5-41d1-8d14-f43388b411f7" xlink:to="loc_us-gaap_RestrictedCashCurrent_ba0d56e9-43d3-429b-bad2-cc4d32a8d806" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesGoodwillRollforwardDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#FairValueofFinancialAssetsandLiabilitiesGoodwillRollforwardDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesGoodwillRollforwardDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_54632eee-0797-4231-8631-5a64ddec3592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_9470eb4f-2ff5-440d-8b2f-3522abe2637c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_54632eee-0797-4231-8631-5a64ddec3592" xlink:to="loc_us-gaap_GoodwillGross_9470eb4f-2ff5-440d-8b2f-3522abe2637c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5b152533-a037-4c74-8554-928c850a0672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_54632eee-0797-4231-8631-5a64ddec3592" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5b152533-a037-4c74-8554-928c850a0672" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#PropertyandEquipmentNetDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74b17e41-dea1-4fc0-9fad-aab89ee1b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_363b9370-a802-4f9d-89c9-fe3e077639ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_74b17e41-dea1-4fc0-9fad-aab89ee1b6da" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_363b9370-a802-4f9d-89c9-fe3e077639ab" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_044d589b-0f07-4f30-989c-d2c09c5555b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_74b17e41-dea1-4fc0-9fad-aab89ee1b6da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_044d589b-0f07-4f30-989c-d2c09c5555b9" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#AccruedExpensesDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3266689-2b6d-423a-90f9-7305af0bb81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3266689-2b6d-423a-90f9-7305af0bb81b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_fe80802d-5ecd-45f5-ad31-490c42921df2" xlink:href="xfor-20231231.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_fe80802d-5ecd-45f5-ad31-490c42921df2" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_bb0de5c4-898b-441c-9b44-6352c9d6b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_bb0de5c4-898b-441c-9b44-6352c9d6b8bd" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedDeferredFinancingFeesCurrent_727a77bb-2605-4488-b98b-2ff64f9c505c" xlink:href="xfor-20231231.xsd#xfor_AccruedDeferredFinancingFeesCurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:to="loc_xfor_AccruedDeferredFinancingFeesCurrent_727a77bb-2605-4488-b98b-2ff64f9c505c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_66038a33-5c6d-4b9e-9764-af450142063d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_eb02ca63-21a6-44f7-a761-7d1d26f43327" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_66038a33-5c6d-4b9e-9764-af450142063d" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_9801ab95-3626-4cec-8495-8f2d1fd06af0" xlink:href="xfor-20231231.xsd#xfor_LongTermDebtIncludingAccretion"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ae0a631a-5478-4c8b-8f64-4fc325a1460e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_9801ab95-3626-4cec-8495-8f2d1fd06af0" xlink:to="loc_us-gaap_LongTermDebt_ae0a631a-5478-4c8b-8f64-4fc325a1460e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_052f0e67-e85d-4edc-a838-2e9de692c447" xlink:href="xfor-20231231.xsd#xfor_AccretionOnLongTermDebt"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_9801ab95-3626-4cec-8495-8f2d1fd06af0" xlink:to="loc_xfor_AccretionOnLongTermDebt_052f0e67-e85d-4edc-a838-2e9de692c447" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_f6cf06c5-ed41-4b15-b704-c6ab98c93c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_9801ab95-3626-4cec-8495-8f2d1fd06af0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_f6cf06c5-ed41-4b15-b704-c6ab98c93c6a" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#LongTermDebtFuturePrincipalPaymentsDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment_6e34035e-1c92-4156-98c5-bf59a639f8ae" xlink:href="xfor-20231231.xsd#xfor_LongTermDebtAndEOTPayment"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7dadb9fd-3792-48af-9a76-b7b320c2a9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_6e34035e-1c92-4156-98c5-bf59a639f8ae" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7dadb9fd-3792-48af-9a76-b7b320c2a9cd" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2c109224-a32c-4773-98a9-30f2604f7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_6e34035e-1c92-4156-98c5-bf59a639f8ae" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2c109224-a32c-4773-98a9-30f2604f7fe8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5a5df631-fbdd-49b2-be92-63305d014a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_6e34035e-1c92-4156-98c5-bf59a639f8ae" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5a5df631-fbdd-49b2-be92-63305d014a66" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4f7e80ba-b375-4cae-8933-97aaea4afa85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e2e2c7ae-4b4a-492f-96e3-30fae049c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4f7e80ba-b375-4cae-8933-97aaea4afa85" xlink:to="loc_us-gaap_OperatingLeaseCost_e2e2c7ae-4b4a-492f-96e3-30fae049c72e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_1fdeb68e-6378-4ed9-951d-db7ca1cd002f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4f7e80ba-b375-4cae-8933-97aaea4afa85" xlink:to="loc_us-gaap_ShortTermLeaseCost_1fdeb68e-6378-4ed9-951d-db7ca1cd002f" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20231231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_570b62ee-d046-48d7-b758-3c6730e58826" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_570b62ee-d046-48d7-b758-3c6730e58826" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_81c90e21-6883-4a35-8705-9ea81d0bb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_81c90e21-6883-4a35-8705-9ea81d0bb6b0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7e3f8ff-dc56-49d8-9613-9a415d922eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a7e3f8ff-dc56-49d8-9613-9a415d922eb8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e57747f-e60b-4702-ac49-48782cdeba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e57747f-e60b-4702-ac49-48782cdeba6a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a75f37e9-a39f-4984-a1c5-0c1620bc4e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155920ed-9fc8-4ca5-8c0c-64cc9296685e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a75f37e9-a39f-4984-a1c5-0c1620bc4e06" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20231231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6956d186-9da4-4704-9841-377ab2ca471a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_201bc0e9-3f44-422f-a813-95483aaad6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6956d186-9da4-4704-9841-377ab2ca471a" xlink:to="loc_us-gaap_OperatingLeaseLiability_201bc0e9-3f44-422f-a813-95483aaad6d5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a5e287d-a04c-42d5-93f1-abf5b59d40ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6956d186-9da4-4704-9841-377ab2ca471a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a5e287d-a04c-42d5-93f1-abf5b59d40ee" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0b2a89c-1630-41f5-941f-a5c73eb2eb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_164244e0-5cac-4186-8cde-07e32b8cb95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0b2a89c-1630-41f5-941f-a5c73eb2eb68" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_164244e0-5cac-4186-8cde-07e32b8cb95a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c22f38b7-bc6f-40ee-a9e8-4810893c4b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c0b2a89c-1630-41f5-941f-a5c73eb2eb68" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c22f38b7-bc6f-40ee-a9e8-4810893c4b70" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ed10562a-5299-40d5-85af-775a2f69f967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ed10562a-5299-40d5-85af-775a2f69f967" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_39b01007-9646-44ce-a67e-06224fb1defa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_39b01007-9646-44ce-a67e-06224fb1defa" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_74c21d8d-e075-40e4-b8b8-30a138584b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_74c21d8d-e075-40e4-b8b8-30a138584b7e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_22848274-783d-45f1-bedc-4bfdefa4aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>

<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_22848274-783d-45f1-bedc-4bfdefa4aba5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_c1bb7d06-1d6e-432d-9e75-5ee54277013b" xlink:href="xfor-20231231.xsd#xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_c1bb7d06-1d6e-432d-9e75-5ee54277013b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a472e403-ec99-4419-87d8-27a7651e3dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>

<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac39f211-6c2f-4717-b0ca-5c335590ab42" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a472e403-ec99-4419-87d8-27a7651e3dac" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="simple" xlink:href="xfor-20231231.xsd#IncomeTaxesDeferredIncomeTaxAssetDetails"/>

<link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3074bc09-ae6c-4376-a035-e41672b997c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_61335a6e-4229-4f0a-ab19-7fd4270fc49a" xlink:href="xfor-20231231.xsd#xfor_DeferredTaxLiabilityRightOfUseAsset"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3074bc09-ae6c-4376-a035-e41672b997c1" xlink:to="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_61335a6e-4229-4f0a-ab19-7fd4270fc49a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e6f8468a-f0a2-4467-b152-57f767f6fca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b6a611b4-4b38-43c0-9a4f-b4db4e6bba70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e6f8468a-f0a2-4467-b152-57f767f6fca7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b6a611b4-4b38-43c0-9a4f-b4db4e6bba70" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_68a47ef5-4fe4-41fb-b598-53d1a2b4ac46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e6f8468a-f0a2-4467-b152-57f767f6fca7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_68a47ef5-4fe4-41fb-b598-53d1a2b4ac46" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_da133853-a50f-478b-8c86-3b347f6b5a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_da133853-a50f-478b-8c86-3b347f6b5a03" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d5a7d37c-d37d-40e8-ae94-97436b13f751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d5a7d37c-d37d-40e8-ae94-97436b13f751" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetLeaseLiability_6c254259-d988-4fdd-8ae5-44771d7d56ce" xlink:href="xfor-20231231.xsd#xfor_DeferredTaxAssetLeaseLiability"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:to="loc_xfor_DeferredTaxAssetLeaseLiability_6c254259-d988-4fdd-8ae5-44771d7d56ce" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_233836e6-8c6c-41ae-b8ba-66741e6348ed" xlink:href="xfor-20231231.xsd#xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:to="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_233836e6-8c6c-41ae-b8ba-66741e6348ed" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d9a29e97-2c5d-497e-9bcc-b7e2f304379d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1afc2595-b064-4b9f-a43a-58c88d8e1414" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d9a29e97-2c5d-497e-9bcc-b7e2f304379d" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6d3fe436-8b34-44e9-a05c-9f3e24c72e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_77571f54-91be-4a71-9e4b-9611f9a09985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6d3fe436-8b34-44e9-a05c-9f3e24c72e69" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_77571f54-91be-4a71-9e4b-9611f9a09985" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c992aeca-44e1-4dd6-951b-74d5dac43bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6d3fe436-8b34-44e9-a05c-9f3e24c72e69" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c992aeca-44e1-4dd6-951b-74d5dac43bd3" xlink:type="arc"/>

</link:calculationLink>

</link:linkbase>

28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/23  X4 Pharmaceuticals, Inc.          10-Q        9/30/23   75:6.9M                                   Workiva Inc Wde… FA01/FA
 8/10/23  X4 Pharmaceuticals, Inc.          10-Q        6/30/23   76:7.4M                                   Workiva Inc Wde… FA01/FA
 5/16/23  X4 Pharmaceuticals, Inc.          8-K:1,3,7,8 5/15/23   16:4.6M                                   Workiva Inc Wde… FA01/FA
 3/21/23  X4 Pharmaceuticals, Inc.          10-K       12/31/22   96:34M                                    Workiva Inc Wde… FA01/FA
12/09/22  X4 Pharmaceuticals, Inc.          8-K:1,8    12/06/22   16:953K                                   Workiva Inc Wde… FA01/FA
11/09/22  X4 Pharmaceuticals, Inc.          8-K:5      11/07/22   11:265K                                   Workiva Inc Wde… FA01/FA
 9/01/22  X4 Pharmaceuticals, Inc.          8-K:3,5     9/01/22   11:2.9M                                   Workiva Inc Wde… FA01/FA
 7/01/22  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 6/30/22   16:1M                                     Workiva Inc Wde… FA01/FA
 3/17/22  X4 Pharmaceuticals, Inc.          10-K       12/31/21  100:10M                                    Workiva Inc Wde… FA01/FA
 3/03/22  X4 Pharmaceuticals, Inc.          8-K:1,3,8   3/03/22   13:744K                                   Workiva Inc Wde… FA01/FA
 1/14/22  X4 Pharmaceuticals, Inc.          8-K:1,9     1/14/22   13:727K                                   Workiva Inc Wde… FA01/FA
11/05/21  X4 Pharmaceuticals, Inc.          8-K:1,3    11/05/21   13:735K                                   Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          10-K       12/31/20  100:12M                                    Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 3/18/21   17:1M                                     Workiva Inc Wde… FA01/FA
 8/07/20  X4 Pharmaceuticals, Inc.          S-3                    8:1.3M                                   Donnelley … Solutions/FA
 6/10/20  X4 Pharmaceuticals, Inc.          S-8         6/10/20    5:331K                                   Workiva Inc Wde… FA01/FA
 5/07/20  X4 Pharmaceuticals, Inc.          10-Q        3/31/20   73:7.2M                                   Workiva Inc Wde… FA01/FA
 3/12/20  X4 Pharmaceuticals, Inc.          10-K       12/31/19  115:15M                                    Workiva Inc Wde… FA01/FA
11/27/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9  11/25/19    7:474K                                   Donnelley … Solutions/FA
 6/19/19  X4 Pharmaceuticals, Inc.          8-K:5,9     6/17/19    7:265K                                   Donnelley … Solutions/FA
 5/13/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:543K                                   Donnelley … Solutions/FA
 4/15/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9   4/12/19    6:455K                                   Donnelley … Solutions/FA
 4/03/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:912K                                   Donnelley … Solutions/FA
 3/13/19  X4 Pharmaceuticals, Inc.          8-K:2,3,5,8 3/11/19   22:2.6M                                   Donnelley … Solutions/FA
11/27/18  X4 Pharmaceuticals, Inc.          8-K:1,5,7,811/26/18   10:8.9M                                   Donnelley … Solutions/FA
11/20/17  X4 Pharmaceuticals, Inc.          8-K:5,9    11/20/17    3:176K                                   Donnelley … Solutions/FA
11/06/17  X4 Pharmaceuticals, Inc.          S-1/A                  8:4.3M                                   Donnelley … Solutions/FA
10/20/17  X4 Pharmaceuticals, Inc.          S-1                   49:9.2M                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001628280-24-012578 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

X4 Pharmaceuticals, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Thursday, 3/21/24, at 5:08pm ET · For: 12/31/23 · Accession #: 1628280-24-12578 · File #: 1-38295

Annual Report — Form 10-K — SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — xfor-20231231_cal

This Exhibit is an XBRL File.

28 Previous Filings that this Filing References

Annual Report — Form 10-K — SEA’34

Filing Table of Contents